Karim A. Benhadji
- Oncology top 1%
- Pancreatic and Hepatic Oncology Research 30
- Colorectal Cancer Treatments and Studies 15
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 11
- Hepatology top 5%
- Immunology top 5%
- Molecular Biology top 5%
- TGF-β signaling in diseases 23
- Fibroblast Growth Factor Research 17
- PI3K/AKT/mTOR signaling in cancer 17
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 15
-
- Lung Cancer Treatments and Mutations 11
- Co-authors
- Ivelina GueorguievaAnn CleverlyShawn T. EstremSandrine FaivreMichael LahnKyla DriscollÉric RaymondRobin Kate Kelley
- Cited by
- OncologyCancer ResearchHepatology
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Oncology (22 papers)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Karim A. Benhadji
115 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Oncology 2.1k
- Cancer Research 540
- Hepatology 257
- Immunology 669
- Molecular Biology 1.8k
Countries citing papers authored by Karim A. Benhadji
This map shows the geographic impact of Karim A. Benhadji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim A. Benhadji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim A. Benhadji more than expected).
Fields of papers citing papers by Karim A. Benhadji
This network shows the impact of papers produced by Karim A. Benhadji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim A. Benhadji. The network helps show where Karim A. Benhadji may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Karim A. Benhadji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancerbreakdown → | 2023 | 183 |
| 3 | 2023 | 1 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 6 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 36 | |
| 9 | 2022 | 12 | |
| 10 | Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Studybreakdown → | 2021 | 171 |
| 11 | 2021 | 6 | |
| 12 | 2021 | 29 | |
| 13 | 2020 | 14 | |
| 14 | 2020 | 3 | |
| 15 | 2019 | 56 | |
| 16 | 2015 | 14 | |
| 17 | 2015 | 25 | |
| 18 | 2013 | 14 | |
| 19 | 2011 | 3 | |
| 20 | 2009 | 44 |
About Karim A. Benhadji
Karim A. Benhadji is a scholar working on Oncology, Biological Psychiatry and Gastroenterology, having authored 117 papers that have together received 3.8k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (30 papers), TGF-β signaling in diseases (23 papers), Fibroblast Growth Factor Research (17 papers), PI3K/AKT/mTOR signaling in cancer (17 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Colorectal Cancer Treatments and Studies (15 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer, Hypoxia, and Metabolism (11 papers). The work is most often cited by research in Oncology (2.1k citations), Cancer Research (540 citations) and Hepatology (257 citations). Karim A. Benhadji has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Ivelina Gueorguieva, Ann Cleverly, Shawn T. Estrem, Sandrine Faivre, Michael Lahn, Kyla Driscoll, Éric Raymond, Robin Kate Kelley, Claire Smith and Susan C. Guba. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.